Breaking News Instant updates and real-time market news.

DCPH

Deciphera

$22.77

-0.64 (-2.73%)

, BPMC

Blueprint Medicines

$75.97

-2.2 (-2.81%)

05:34
06/03/19
06/03
05:34
06/03/19
05:34

Deciphera price target raised to $55 from $50 at Piper Jaffray

Piper Jaffray analyst Christopher Raymond raised his price target for Deciphera Pharmaceuticals (DCPH) to $55 from $50 after hosting investor meetings with management and reviewing competitor Blueprint Medicines' (BPMC) avapritinib update over the weekend. Given the "significant" valuation-gap between the two companies, driven by misperceptions around their respective KIT inhibitors, new money investment into Deciphera "right here makes a lot of sense," Raymond tells investors in a research note. He keeps an Overweight rating on the shares.

DCPH

Deciphera

$22.77

-0.64 (-2.73%)

BPMC

Blueprint Medicines

$75.97

-2.2 (-2.81%)

  • 04

    Jun

  • 11

    Jun

  • 18

    Jun

DCPH Deciphera
$22.77

-0.64 (-2.73%)

01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
03/14/19
PIPR
03/14/19
NO CHANGE
Target $50
PIPR
Overweight
Deciphera development of ripretinib 'progressing nicely', says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $50 price target on Deciphera after its in-line Q4 results, saying the company's development of ripretinib is progressing nicely with ongoing phase 3 enrollment in INTRIGUE study and results for INVICTUS study expected later this year. The analyst remains positive on the shares given the company's "catalyst-rich" second half of the year on tap.
BPMC Blueprint Medicines
$75.97

-2.2 (-2.81%)

01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
03/28/19
COWN
03/28/19
NO CHANGE
COWN
Outperform
Blueprint closing gap with Loxo in RET+ tumors, says Cowen
Cowen analyst Marc Frahm said he believes the regulatory updates offered last night by Blueprint Medicines (BPMC) for avapritinib, BLU-667 and BLU-782 are all incremental positives, but he views the new clinical data for BLU-667 as "much more newsworthy." His prior survey of lung cancer physicians and investors to assess what response rate from BLU-667 they would consider competitive to Loxo Oncology's (LOXO) LOXO-292 yielded an average physician response of 59% and average investor response was 62%. Given that Blueprint reported an ORR of 62% within the second-line NSCLC cohort of 34 patients, Frahm think consensus is likely to shift towards BLU-667 capturing a meaningful share of the RET+ market, he tells investors. He keeps an Outperform rating on Blueprint Medicines.
04/03/19
MSCO
04/03/19
INITIATION
Target $112
MSCO
Overweight
Blueprint Medicines initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated Blueprint Medicines with an Overweight rating and $112 price target, calling avapritinib, the company's s lead asset for the treatment of certain types of gastrointestinal stromal tumors, the key driver of his valuation. Avapritinib is on track to be submitted to the FDA in Q2, which should potentially put the drug on the market by year-end, and data so far show it to be a promising therapy, Lebowitz tells investors. He projects gastrointestinal stromal tumor revenues approaching $600M by 2026.
05/23/19
GSCO
05/23/19
INITIATION
Target $125
GSCO
Buy
Blueprint Medicines assumed with a Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter assumed coverage of Blueprint Medicines with a Buy rating and $125 price target. The firm previously had a Buy rating on the shares. The analyst recommends owning Blueprint for the near- and long-term growth outlook of its two impending launches, avapritinib for PDGFRalpha D842V mutant/4L gastrointestinal stromal tumors and BLU-667 for RET-altered non-small cell lung cancer. He assumes peak unadjusted global sales of $1.7B.

TODAY'S FREE FLY STORIES

01:55
10/23/19
10/23
01:55
10/23/19
01:55
General news
Asian Market Update: »

Asian Market Update:…

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:08
10/22/19
10/22
21:08
10/22/19
21:08
Earnings
Breaking Earnings news story on Euronet »

Euronet sees Q4 EPS $1.61…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:07
10/22/19
10/22
21:07
10/22/19
21:07
Hot Stocks
Euronet says revenue growth would have been stronger if not for strong USD »

CEO Michael Brown says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:06
10/22/19
10/22
21:06
10/22/19
21:06
Hot Stocks
Euronet reports Q3 adjusted EBITDA $227.3M vs. $181.4M last year »

Reports Q3 transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:04
10/22/19
10/22
21:04
10/22/19
21:04
Earnings
Euronet reports Q3 adjusted EPS $2.84, consensus $2.80 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

FFWM

First Foundation

$15.50

0.16 (1.04%)

21:03
10/22/19
10/22
21:03
10/22/19
21:03
Earnings
First Foundation reports Q3 EPS 39c, consensus 36c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

KMB

Kimberly-Clark

$129.57

-9.74 (-6.99%)

20:36
10/22/19
10/22
20:36
10/22/19
20:36
Upgrade
Kimberly-Clark rating change at Deutsche Bank »

Kimberly-Clark upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BA

Boeing

$337.45

6.33 (1.91%)

, TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

20:25
10/22/19
10/22
20:25
10/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BA

Boeing

$337.45

6.33 (1.91%)

TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

LLY

Eli Lilly

$110.00

2.06 (1.91%)

CAT

Caterpillar

$133.69

1.47 (1.11%)

ANTM

Anthem

$260.28

7.12 (2.81%)

BX

Blackstone

$49.08

-0.025 (-0.05%)

BSX

Boston Scientific

$38.21

-0.45 (-1.16%)

GD

General Dynamics

$179.92

4.49 (2.56%)

NSC

Norfolk Southern

$188.85

2.68 (1.44%)

HLT

Hilton

$90.81

-1.57 (-1.70%)

FCX

Freeport McMoRan

$9.92

0.1 (1.02%)

IVZ

Invesco

$16.03

-0.115 (-0.71%)

OC

Owens Corning

$63.41

-0.055 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 02

    Dec

  • 07

    Dec

ACRS

Aclaris Therapeutics

$1.62

0.215 (15.36%)

20:13
10/22/19
10/22
20:13
10/22/19
20:13
Upgrade
Aclaris Therapeutics rating change at SVB Leerink »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

AMGN

Amgen

$204.84

1.93 (0.95%)

19:39
10/22/19
10/22
19:39
10/22/19
19:39
Hot Stocks
Amgen CFO David Meline to retire »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

TRV

Travelers

$130.22

-11.55 (-8.15%)

19:31
10/22/19
10/22
19:31
10/22/19
19:31
Upgrade
Travelers rating change at Deutsche Bank »

Travelers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GOOG

Alphabet

$1,242.78

-3.45 (-0.28%)

, GOOGL

Alphabet Class A

$1,241.08

-3.15 (-0.25%)

19:09
10/22/19
10/22
19:09
10/22/19
19:09
Periodicals
State AGs plan Google antitrust meeting next month, Reuters says »

U.S. state attorneys…

GOOG

Alphabet

$1,242.78

-3.45 (-0.28%)

GOOGL

Alphabet Class A

$1,241.08

-3.15 (-0.25%)

FB

Facebook

$182.27

-7.55 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

CISN

Cision

$10.08

1.63 (19.29%)

19:03
10/22/19
10/22
19:03
10/22/19
19:03
Downgrade
Cision rating change at BMO Capital »

Cision downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MANH

Manhattan Associates

$74.47

-2.02 (-2.64%)

, TER

Teradyne

$59.24

-0.83 (-1.38%)

18:55
10/22/19
10/22
18:55
10/22/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MANH

Manhattan Associates

$74.47

-2.02 (-2.64%)

TER

Teradyne

$59.24

-0.83 (-1.38%)

CSL

Carlisle

$144.97

-0.27 (-0.19%)

USNA

Usana

$72.62

2.92 (4.19%)

NAVI

Navient

$12.16

0.19 (1.59%)

DFS

Discover

$81.30

0.85 (1.06%)

HNGR

Hanger

$20.50

0.39 (1.94%)

MRNA

Moderna

$15.90

0.42 (2.71%)

REZI

Resideo

$15.17

0.03 (0.20%)

IRBT

iRobot

$53.88

-1.82 (-3.27%)

TXN

Texas Instruments

$128.61

-2.32 (-1.77%)

INTC

Intel

$52.00

-0.12 (-0.23%)

ADI

Analog Devices

$110.91

-0.18 (-0.16%)

AVGO

Broadcom

$287.54

-2.03 (-0.70%)

NVDA

Nvidia

$195.52

-0.64 (-0.33%)

QCOM

Qualcomm

$78.46

-0.5 (-0.63%)

AMD

AMD

$31.51

-0.54 (-1.68%)

HA

Hawaiian Holdings

$30.14

0.67 (2.27%)

SIX

Six Flags

$51.22

-0.62 (-1.20%)

WHR

Whirlpool

$160.72

0.18 (0.11%)

BYD

Boyd Gaming

$26.17

0.24 (0.93%)

CMG

Chipotle

$831.69

-20.195 (-2.37%)

SNAP

Snap

$14.00

-0.58 (-3.98%)

SKX

Skechers

$38.03

0.55 (1.47%)

SLNO

Soleno Therapeutics

$1.50

0.03 (2.04%)

NOW

ServiceNow

$228.26

-12.315 (-5.12%)

NKE

Nike

$95.61

-0.61 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

  • 23

    Oct

IIPR

Innovative Industrial Properties

$72.50

-1.2 (-1.63%)

18:53
10/22/19
10/22
18:53
10/22/19
18:53
Hot Stocks
Innovative Industrial Properties investing $46.6M in two IL properties »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CISN

Cision

$10.08

1.63 (19.29%)

18:51
10/22/19
10/22
18:51
10/22/19
18:51
Downgrade
Cision rating change at BMO Capital »

Cision downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LOGI

Logitech

$39.97

-0.75 (-1.84%)

18:42
10/22/19
10/22
18:42
10/22/19
18:42
Hot Stocks
Logitech CEO: We had a solid quarter despite macroeconomic noise »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

HAS

Hasbro

$100.00

-20.11 (-16.74%)

18:23
10/22/19
10/22
18:23
10/22/19
18:23
Hot Stocks
Hasbro CEO: We believe we can grow in Q4 »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.04 (-0.35%)

, SPX

S&P 500

$0.00

(0.00%)

18:22
10/22/19
10/22
18:22
10/22/19
18:22
General news
Trump tweets 'good news happening' on Turkey, Syria, Middle East »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.04 (-0.35%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$69.11

0.37 (0.54%)

18:20
10/22/19
10/22
18:20
10/22/19
18:20
Periodicals
NY AG's office says Exxon should pay up to $1.6B in climate trial, NYP says »

Kevin Wallace, a lawyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XOM

Exxon Mobil

$69.11

0.37 (0.54%)

17:58
10/22/19
10/22
17:58
10/22/19
17:58
Periodicals
Exxon lawyer slams NY climate suit as trial opens, Bloomberg says »

Exxon Mobil attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:57
10/22/19
10/22
17:57
10/22/19
17:57
Hot Stocks
Teradyne jumps 6% after quarterly results, guidance based on 5G demand »

Shares of semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:53
10/22/19
10/22
17:53
10/22/19
17:53
Earnings
Teradyne sees Q4 EPS 73c-84c, consensus 61c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

LEVI

Levi Strauss

$17.59

0.58 (3.41%)

17:52
10/22/19
10/22
17:52
10/22/19
17:52
Hot Stocks
Levi Strauss EVP Love sells 204K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$46.15

0.48 (1.05%)

, WFC

Wells Fargo

$50.63

0.18 (0.36%)

17:51
10/22/19
10/22
17:51
10/22/19
17:51
Periodicals
BNY Mellon vice chairman leaves lender, WSJ says »

Bill Daley, former White…

BK

BNY Mellon

$46.15

0.48 (1.05%)

WFC

Wells Fargo

$50.63

0.18 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 12

    Nov

  • 14

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.